SK Bioscience Wins Patent Lawsuit Against Pfizer Over 13-valent Pneumococcal Conjugate Vaccine

The Supreme Court of Korea ruled in favor of SK bioscience in a patent infringement lawsuit filed by Pfizer regarding SK bioscience's 13-valent pneumococcal conjugate vaccine (PCV13), allowing SK bioscience to export individual components of PCV13 to countries with high vaccine demand and pursue technology transfers. This ruling overturns Pfizer's claim that SK bioscience's exports infringed on its Prevnar 13 vaccine patent, and clears the way for SK bioscience to expand its presence in the global pneumococcal vaccine market, including domestic sales of SKYPneumo from 2027 and the development of a 21-valent vaccine with Sanofi.

Analysis

SK bioscience has secured a significant legal victory as the Supreme Court of Korea ruled in its favor in a patent infringement lawsuit initiated by Pfizer concerning SK bioscience's 13-valent pneumococcal conjugate vaccine (PCV13). The court affirmed that SK bioscience's export of PCV13 individual conjugate bulk substances and research-use finished products did not infringe Pfizer's Prevnar 13 composition patent. This ruling is pivotal, immediately enabling SK bioscience to pursue exports of PCV13 components to high-demand markets like Southeast Asia and Latin America and to engage in technology transfers, strategically circumventing previous restrictions while its domestic SKYPneumo vaccine sales remain on hold until 2027. This legal success, alongside a recent favorable outcome in a patent invalidation suit against Moderna's mRNA vaccine technology patent in Korea, underscores SK bioscience's growing strength in navigating complex intellectual property challenges. The company's pipeline is further bolstered by its collaboration with Sanofi on a 21-valent pneumococcal vaccine, which entered Phase 3 global clinical trials in late 2024, and a next-generation pneumococcal vaccine. For Pfizer, this decision likely means increased competition for its Prevnar 13 franchise from SK bioscience's PCV13 components in certain international markets sooner than the 2027 Korean patent expiry. Moderna faces a specific challenge to its mRNA patent portfolio in Korea. Conversely, Sanofi's partnership on advanced pneumococcal vaccines is with a company demonstrating enhanced operational freedom and IP resilience.

Key Decisions for Investors

• Recognize SK bioscience's significantly improved competitive positioning in the pneumococcal vaccine market, driven by its legal victories enabling near-term PCV13 component exports and bolstering its outlook for future proprietary and partnered (with Sanofi) vaccine launches.
• Pfizer (PFE) investors should evaluate the increased risk of market share erosion for Prevnar 13 in regions targeted by SK bioscience, potentially occurring sooner than the 2027 Korean patent expiration for domestic sales of SKYPneumo.
• Moderna (MRNA) investors ought to consider the Korean patent invalidation as a data point indicating potential ongoing intellectual property headwinds for its mRNA technology in specific international jurisdictions.
• For Sanofi (SNY), this outcome for its partner SK bioscience can be viewed as a de-risking event for their joint development of advanced pneumococcal vaccines, potentially improving the collaboration's prospects.